Citius Pharmaceuticals (NASDAQ:CTXR) Posts Earnings Results, Misses Expectations By $0.01 EPS

Citius Pharmaceuticals (NASDAQ:CTXR) released its earnings results on Monday. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01), Zacks reports.

Citius Pharmaceuticals Trading Down 0.9 %

Shares of NASDAQ CTXR opened at $0.61 on Wednesday. Citius Pharmaceuticals has a 12 month low of $0.48 and a 12 month high of $1.07. The firm has a market capitalization of $109.31 million, a price-to-earnings ratio of -2.54 and a beta of 1.67. The business has a 50-day moving average of $0.73 and a 200-day moving average of $0.74.

Wall Street Analysts Forecast Growth

CTXR has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Citius Pharmaceuticals in a research note on Friday, May 31st. EF Hutton Acquisition Co. I upgraded Citius Pharmaceuticals to a “strong-buy” rating in a research report on Monday, July 15th.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.